Axsome Therapeutics
AXSM
109 hedge funds and large institutions have $477M invested in Axsome Therapeutics in 2019 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 13 closing their positions.
338% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 13
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
162% more call options, than puts
Call options by funds: $28.5M | Put options by funds: $10.9M
121% more capital invested
Capital invested by funds: $216M → $477M (+$261M)
68% more funds holding
Funds holding: 65 → 109 (+44)
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
10.59% more ownership
Funds ownership: 44.53% → 55.12% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$24.6M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$15.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.6M |
| 5 |
VMI
VHCP Management III
New York
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$39.1M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$8.57M |
| 3 |
Millennium Management
New York
|
-$7.51M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$4.87M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$4.13M |
AXSM Hedge Fund Activity: Q2 2019 in Review
109 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2019, worth a combined $477M — up 121% from $216M a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new AXSM positions and 13 closed out — a net gain of 44 holders — while 25 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $24.6M. The largest seller was RA Capital Management, cutting an estimated $39.1M.
- 109 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2019, up from 65 in Q1 2019.
- Funds reported $477M of Axsome Therapeutics stock for Q2 2019, up 121% quarter-over-quarter.
- 57 funds opened new Axsome Therapeutics positions in Q2 2019 and 13 closed out, a net change of +44 holders.
- The largest Axsome Therapeutics buyer in Q2 2019 was BlackRock, an estimated $24.6M added.
- The largest Axsome Therapeutics seller in Q2 2019 was RA Capital Management, an estimated $39.1M sold.
Based on aggregated 13F filings for Q2 2019.